FDA Approves Treatment for Low Blood Pressure

Following a Priority Review, the US Food and Drug Administration has approved Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure (BP) in adults with septic or other distributive shock.

Giapreza was approved following a clinical trial of 321 patients with shock and dangerously low BP. Results of the trial showed that significantly more patients had responded to treatment with Giapreza vs placebo.

Patients taking Giapreza should also be treated with prophylactic blood clot treatments, since Giapreza can cause dangerous blood clots with serious consequences, including deep venous thrombosis.

—Christina Vogt

For more Pharmacy Learning Network articles, visit the homepage

To learn about Pharmacy Learning Network Live meetings, click here